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properties are incompletely understood. Herein, we show that homozygous deletion of
the miR-29a/b-1 bicistron results in decreased numbers of hematopoietic stem and
progenitor cells (HSPCs), decreased HSC self-renewal, and increased HSC cell cycling
and apoptosis. The HSPC phenotype is specifically due to loss ofmiR-29a, becausemiR-29b expression is unaltered inmiR-29a/b-1-
null HSCs, and only ectopic expressionofmiR-29a restoresHSPC function both in vitro and in vivo. HSCs lackingmiR-29a/b-1 exhibit
widespread transcriptional dysregulation and adopt gene expression patterns similar to normal committed progenitors. A number of
predicted miR-29 target genes, including Dnmt3a, are significantly upregulated in miR-29a/b-1-null HSCs. The loss of negative
regulationofDnmt3abymiR-29a is amajor contributor to themiR-29a/b-1-null HSPCphenotype, as both in vitroDnmt3a short hairpin
RNA knockdown assays and a genetic haploinsufficiency model of Dnmt3a restored the frequency and long-term reconstitution
capacity of HSCs from miR-29a/b-1-deficient mice. Overall, these data demonstrate that miR-29a is critical for maintaining HSC
function through its negative regulation of Dnmt3a. (Blood. 2015;125(14):2206-2216)
Introduction
Hematopoietic stem cells (HSCs) are the only cells in the blood system
capable of giving rise to all mature hematopoietic cells while self-
renewing for the lifetime of an organism.1,2 Although HSCs have been
extensively characterized with respect to expression of their protein-
encoding transcripts,3,4 relatively little is known about the role of
non–protein-encoding RNAs in HSC function, particularly micro-
RNAs (miRNAs).miRNAs are small noncodingRNAs (22-24 nts) that
exert their biological effects bynegatively regulating the stability and/or
translation efficiency of multiple target mRNAs.5 Given the ability of
each miRNA to target hundreds of mRNAs on average, it is not sur-
prising that miRNAs play critical roles in regulating gene networks
involved in stem cell self-renewal, development, and carcinogenesis.6,7
Our laboratory and others have performed miRNA expression
profiling studies usinghighlypurifiedHSCsandcommittedprogenitors
in both themouse and human hematopoietic systems and demonstrated
that different hematopoietic stem and progenitor cell (HSPC) popu-
lations exhibit unique miRNA expression patterns, supporting a role
for miRNAs in their distinctive biological functions.8-11 For example,
miRNAs expressed at high levels in HSCs such as miR-125a/b,12-14
miR-126,15 andmiR-146a16 regulateHSCself-renewalordifferentiation.
More recently,miR-29awas shown to play an important role in directly
regulating innate and adaptive immune responses17 by targeting
interferon-g18 or indirectly by protecting the thymus from inappro-
priate involution through suppression of the interferon-a receptor.19
ThemiR-29 family is alsomore broadly relevant to stemcell biology, as
miR-29b recentlywas shown tobeupregulatedbySox2 and required for
reprogramming of fibroblasts into induced pluripotent stem cells.20
Although little is known about how miR-29a transcript levels are
regulated, CCAAT/enhancer-binding protein alpha (CEBPA) has been
reported to positively regulate the miR-29a/b-1 cluster and expression
ofmiR-29a/b is suppressed in acute myeloid leukemia (AML) patients
with impaired CEBPA function.21
To understand the physiologic role of miR-29a in normal hema-
topoietic development, we evaluated HSPCs in mice harboring a ge-
netic deletion of themiR-29a/b-1 bicistron.19 Here we demonstrate that
deletion of the miR-29a/b-1 bicistron results in decreased HSC self-
renewal and long-term reconstitution capacity. This loss of HSC
function is associated with increased HSC cell cycling and apoptosis,
as well as acquisition of a gene expression profile similar to more
differentiated hematopoietic progenitors. Among the differentially
expressed transcripts are multiple predicted miR-29a targets including
Dnmt3a. By crossing miR-29a/b-1 heterozygous mice to Dnmt3a
heterozygous mice, we show that the functional defects observed in
miR-29a-null HSCs are largely mediated via abrogation of its negative
regulation of Dnmt3a expression. Overall, these studies indicate that
miR-29a is essential in maintaining HSC function and mediates its
effects by modulating the activity of the epigenetic regulator Dnmt3a.
Materials and methods
Retrovirus preparation and transduction
TheDnmt3a short hairpin RNA (shRNA) constructs were cloned into the pMig
plasmid and were gifts from Dr Iannis Aifantis (New York University, New
York, NY). Retroviral preparation and donor cell infections/transplantations
were performed as previously described.9 The ability of 2 shRNA clones (197
and 6567) to knock down Dnmt3a was confirmed in NIH/3T3 cells. DNMT3a
antibody (2160S; Cell Signaling) was used to confirm the protein levels after
knockdown.
Mice/transplantations
The generation of miR-29a/b-1-null mice was previously described.19 Donor and
recipient mice (C57BL/6 and B6.SJL-Ptprca Pepcb/BoyJ, respectively) were
bred and maintained in the Memorial Sloan Kettering Cancer Center mouse
facility.Dnmt3awt/fl[Mx-Cre]micewere crossedwithmiR-29a/b-1Hetmice, and
their progeny were injected intraperitoneally 6 times with 300 mg polyinosinic:
polycytidylic acid (Sigma) in phosphate-buffered saline every other day to
induce deletion of miR-29a/b-1 floxed alleles. All progeny contained Mx-Cre
knockin to diminish the bias fromCre expression. Recipientswere retro-orbitally
transplanted following lethal irradiation using a g radiation source (9.5 Gy total)
and maintained on antibiotics (Sulfatrim) for 6 weeks following transplantation.
Total bone marrow cells (2 million donor cells) or magnetic bead-enriched
(Miltenyi Biotec) c-Kit1 cells (500 000 cells) were used for noncompetitive or
competitive transplants, respectively. Competitive transplantations were per-
formed with equal numbers of competitor bone marrow cells. Following
transplant, the peripheral blood was sampled monthly to evaluate donor
chimerism and lineage composition. All mouse procedures were performed in
accordance with institutional guidelines as described in an Institutional Animal
Care and Use Committee (IACUC) approved protocol.
miRNA expression analysis
The expression of miR-29a, miR-29b, and miR-29c was measured using a
QuantiMir kit per the manufacturer’s instructions (System Biosciences). Syn-
thesized oligonucleotides containing mature miRNA sequences were used as
primers for miR-29 family member genes. Total RNA was prepared from total or
c-Kit1-enriched bonemarrow cells using the RNeasyMini Kit (Qiagen).Mouse
snoRNA202 was used as an endogenous control to normalize for total RNA
loaded.
Methylcellulose colony forming assays
To evaluate self-renewal and proliferation of HSPCs, fluorescence-activated cell
sorter (FACS)-purified c-Kit1HSPCswere cultured inmethylcellulosemedium
supplemented with cytokines (Methocult GFM3434; Stem Cell Technologies).
Colony numbers were counted 12 days after plating. Serial replating cultures
were performed by harvesting cells from methylcellulose media, followed by
plating 20 000 cells in fresh methylcellulose.
Cell staining and flow cytometry
Mouse bonemarrow cells were harvested and stained as previously described.22
Briefly, antibodies used in this study include a lineage (Lin) cocktail containing
antibodies against Ter-119 (clone Ter-119), B220 (RA3-6B2), CD3e
(145-2C11), CD4 (GK1.5), CD8 (53-6.7), Gr-1 (RB6-8C5), and Mac-1
(M1/70) antibodies, conjugated with either phycoerythrin (PE)-Cy5 or PE-Cy7
(eBiosciences). Additional antibodies used to identify HSPCs included CD16/32
(93) in Alexa eFluor 700, IL7Ra (A7R34) in PE-Cy5, CD45.1 (A20) in
PE-Cy7, c-Kit (2B8) in allophycocyanin (APC)-eFluor 780, Gr-1 (RB6-8C5)
in PE, CD45.2 (104) in Alexa eFluor 700, CD34 (RAM34) in fluorescein
isothiocyanate, Flk2/Flt3 (A2F10) in PE (all fromeBiosciences), aswell as Sca-1
(E13-161.7) in Pacific Blue and CD150 (TC15-12F12.2) in PE (both from
BioLegend). After staining, cells were analyzed and sorted using a FACSAria
II (Becton Dickinson). All cell populations were double sorted, and a purity
of .90% was routinely achieved. Flow cytometry data were analyzed using
Flowjo software (TreeStar, Inc.).
Cell cycle and apoptosis analysis
For cell cycle analysis, bone marrow cells were stained with antibodies to identify
HSPCs as described above and then fixed using a Fixation/Permeabilization Kit
(eBioscience) and stained with 4,6 diamidino-2-phenylindole (DAPI; Invitro-
gen). 5-Bromo-29-deoxyuridine (BrdU) retention assays were performed by an-
alyzing bone marrow cells 20 hours after intraperitoneal injection with 150 mL
BrdU (10 mg/mL) per mouse (BD Pharmingen). A fluorescein isothiocyanate-
conjugated anti-BrdU antibody was used to detect BrdU content by flow
cytometry. Apoptosis was evaluated using anAnnexin V staining kit per the
manufacturer’s instructions (BD).
Microarray analysis
Total RNA was extracted from double FACS-sorted cell populations using
an RNeasy Mini Kit (Qiagen), Nugen Ovation Pico WTA was used for
preamplification of RNA samples and was hybridized to Illumina Mouse 6
arrays using standard protocols. Array data were analyzed using open source
R/Bioconduct software including lumi and limma packages (R Development
Core Team, 2012). The microarray data were submitted to the Gene Expression
Omnibus (GEO) database (accession number GSE58237). Predicted miR-29a/
b-1 target genes were identified using the online database targetscan.org.23
Data analysis and statistics
Data were summarized and presented using open source R/Bioconductor
software (R Development Core Team, 2012). Statistical tests were performed
using the appropriate software packages accompanying this program, including
a 2-tailed t test between groups (*P , .05; **P , .01); log-rank tests were
used for comparison of Kaplan-Meier curves.24 Error bars in bar graphs indi-
cate standard error of the mean (SEM).
Results
miR-29a/b-1 positively regulates hematopoietic stem/progenitor
cell number
Todetermine the role ofmiR-29a/b-1 in hematopoiesis,we assessed the
frequencies of HSPCs in mice harboring a constitutive deletion of the
miR-29a/b-1 bicistronic cluster on chromosome 6 by flow cytometry
(FC).19 In adult mice (12-16 weeks old), deletion of miR-29a/b-1
resulted in significantly decreased frequencies of Lin2c-Kit1Sca-11
(LSK) and Lin2c-Kit1Sca-12 (committed progenitors) cells compared
with wild-type (WT) littermates (Figure 1A,C,E). miR-29a/b-12/2
mice also exhibited a 20.1% decrease in bone marrow cellularity
(Figure 1B). Furthermore, deletion of miR-29a/b-1 resulted in signif-
icantly reduced frequencies of populations within the LSK population
(HSCs and multipotent progenitors [MPPs]), as well as in committed
progenitors (common myeloid progenitor [CMP], granulocyte-
macrophage progenitor [GMP], megakaryocyte-erythroid progenitor
[MEP], and common lymphoid progenitor [CLP]; Figure 1A,D,F-G).
Despite these alterations in HSPC composition, miR-29a/b-12/2mice
did not exhibit statistically significant differences in their peripheral
blood counts compared with those of their WT littermates (supple-
mental Figure 1, available on the Blood Web site). In addition, FC
analysis of the peripheral blood failed to demonstrate differences in the
frequencies of myeloid or T cells in miR-29a/b-12/2 mice compared
with WT littermate controls, although miR-29a/b-12/2 mice did
demonstrate a significant decrease in B2201 B cells (supplemental
Figure 2). To determine whether alterations in HSPC composition are
specific to adult hematopoiesis, we evaluated fetal liver hematopoiesis
in E13.5;E14.5 miR-29a/b-12/2 embryos. There was no difference in
HSPC frequencies or total cellularity in fetal liver, indicating a de-
velopmental stage-specific effect of miR-29a/b-1 function (supple-
mental Figure 3A-D). These data indicate that loss of miR-29a/b-1
results in a significant reduction in the number ofHSPCs during steady-
state adult hematopoiesis.
Loss of miR-29a/b-1 results in impaired stem/progenitor cell
colony forming capability
To determinewhether the reduction inHSPCnumbers inmiR-29a/b-1-
deficient mice is due to decreased HSPC self-renewal and/or pro-
liferative capacity, we performed methylcellulose colony formation
assays with serial replating. miR-29a/b-12/2 cells gave rise to fewer
and smaller colonies comparedwithWT littermate controls when 3000
c-Kit1 cells were plated into methylcellulose media (Figure 2A-B).
The reduction in colony forming activity in miR-29a/b-12/2 cells
compared with WT controls was more severe in secondary plating
experiments, and by the third plating, too few cellswere generated from
miR-29a/b-12/2 cells to be replated (Figure 2A).
To investigate the effect ofmiR-29a/b-1 loss on specificHSPCpop-
ulations, we performed colony formation assays using FACS-sorted
HSC, MPP, CMP, GMP, and MEP cells.25-28 All these miR-29a/b-1-
deficient populations exhibited significant reductions in colony
numbers with the exception of GMPs (Figure 2C), but all HSPC pop-
ulations, includingGMPs, gave rise to smaller colonies.Thedifferences
in colony formation were more pronounced in cultures initiated by the
most immature populations (ie,HSCs andMPPs; Figure 2C). Together,
these data indicate that miR-29a/b-1 positively regulates HSPC pro-
liferation and self-renewal capacity.
Figure 1. miR-29a/b-1-null mice exhibit decreased
bone marrow cellularity and significantly reduced
numbers of HSPCs. (A) Representative flow cyto-
metric analyses. Each column includes WT littermate,
miR-29a/b-1 Het, and miR-29a/b-1-null (KO) mice.
Live cells were gated based on propidium iodide ex-
clusion. Prior gates for each subpopulation are indicated
on the top of each column. Specific HSPC populations
and their frequencies were calculated based on total
bone marrow cell counts and were identified as shown.
(B) Total bone marrow cell counts were based on
bilateral femur cell recoveries. (C-G) Summarized results
of bone marrow HSPC frequencies assessed by flow
cytometry. The cell populations evaluated were indicated
at the x-axis, and the y-axis represents the frequencies of
these populations among total bone marrow cells.
Each group included 7 to 10 mice. Error bars indicated
SEM. Statistical significance was calculated using a
Student t test: *P , .05; **P , .01.
miR-29a/b-1-null HSCs exhibit cell-intrinsic defects in
self-renewal in vivo
To further examine the self-renewal defect ofmiR-29a/b-1-null HSCs,
as well as to determine whether the hematologic phenotype is cell in-
trinsic, long-term reconstitution assayswereperformedusing total bone
marrow cells, as well as partially purified HSPC populations. Lethally
irradiatedmice (CD45.1,B6.SJL-PtprcaPepcb/BoyJ)were transplanted
with2million unfractionated,CD45.2-positive bonemarrowcells from
miR-29a/b-1-null (KO), miR-29a/b-11/2 (Het), or WT littermate con-
trols. Donor chimerism was monitored serially in transplanted recip-
ients by sampling the peripheral blood. Although WT and Het bone
marrow cells gave rise to lymphoid and myeloid progeny at similar
frequencies (92.3% and 85.6% donor chimerism, respectively, at week
4 after transplantation), KO bone marrow cells reconstituted trans-
planted recipients poorly (28.5%donor chimerism at week 4), and their
chimerism levels decreased progressively over time (Figure 3A-E).
One possible explanation for the decreased engraftment capacity of
KO HSCs is that they possess intrinsic defects in their bone marrow
homing capacity. To examine this possibility, we competitively trans-
planted 500 000 c-Kit1 cells from WT, Het, and KO mice (CD45.2)
into lethally irradiated congenic recipients (CD45.1), along with
500 000 total bone marrow cells expressing the recipient CD45.1 allele.
After 20 hours, mice were euthanized, and bone marrow cells were
evaluated for the presence of donor cells. Equal numbers of KO, Het,
andWT donor HSCs (Lin2Sca-11c-Kit1Slamf11) were present in the
bonemarrows of recipients, thereby providing no support for a homing
defect (Figure 3F).
Analysis of long-term engraftedmice revealed that transplantedKO
cells contributed to HSPCs at lower levels thanWT littermate controls
(Figure 3G-H). Similar deficits in HSPC engraftment and reconstitution
were observed when 500 000 c-Kit1 bonemarrow cells fromKOmice
were competitively transplanted with 500 000 WT total bone marrow
cells (supplemental Figure 4A-E). Het donor chimerism in the periph-
eral blood was also significantly lower than WT littermates when
transplantationswere performed competitively. These data indicate that
miR-29a/b-1 regulates HSC long-term reconstitution capacity.
To further characterize the defects inmiR-29a/b-1Het HSPC func-
tion, we transplanted total bone marrow cells from noncompetitively
engrafted recipients exhibiting high levels of WT or Het donor chi-
merism (;90%). Secondary transplantation of Het bone marrow cells
gave rise to significantly lower levels of CD45.2 donor chimerism than
WT cells (Het 11.5% vs WT 72.3% at 4 weeks; P , .05), with Het
donor chimerism levels remaining low over time (Figure 3I-M). Both
LSK and committed progenitor cells from Het HSPC transplanted
recipients were present in the BM of secondary recipients at sig-
nificantly lower frequencies at 16 weeks after transplantation
compared with recipients receiving WT cells (Figure 3N), consis-
tent with a gene dosage-dependent role of miR-29a/b-1 in sustaining
HSC self-renewal.
Figure 2. miR-29a/b-1-null HSPCs exhibit de-
creased colony forming capacity in methylcellu-
lose colony assays. (A) Methylcellulose colony assays
were performed using c-Kit1-enriched bone marrow
cells. The first plating was initiated using 3000 c-Kit1
cells from WT, Het, and KO mice. Replatings were
performed using 20 000 cells per well. (B) Photomicro-
graphs of typical colonies generated by WT, Het, and
KO HSPCs on initial plating. (C) Methylcellulose colony
assays were performed using purified HSPCs. Six
populations, including HSC, MPPa, MPPb, CMP, MEP,
and GMP, were double FACS sorted and 150 (HSC,
MPPa, MPPb) or 400 (CMP, MEP, and GMP) cells
were plated. Data shown represent the aggregate
of 3 technical replicates. Error bars indicate SEM.
Statistical significance was calculated using a Student t
test: *P , .05; **P , .01.
Figure 3. miR-29a/b-1-deficient HSCs exhibit reduced self-renewal and reconstitution capacity. (A-E) Donor cell chimerism of total peripheral blood leukocytes or
specific cell lineages in the peripheral blood was examined following total bone marrow cell transplant. Donor chimerism (CD45.21) levels were evaluated following
transplantation of 2 million total bone marrow cells from WT, Het, or KO mice into lethally irradiated recipients. (F) Bone marrow cells from both femurs and tibias were
examined for donor chimerism 20 hours after transplant using the same transplantation protocol used for competitive transplants. Each group includes 6 to 10 recipient mice
transplanted with cells from .3 different donors. (G) Representative flow cytometric analysis of HSPCs in WT, Het, and KO recipients 16 weeks after transplant, previously
gated on LSK cells. (H) Summarized results of flow cytometric analysis of bone marrow cells in recipients 4 months after the second transplantation. (I-M) Donor cell
chimerism of secondary recipients transplanted with total bone marrow cells from primary recipients transplanted with WT or Het cells. (N) Flow cytometric analysis of HSPCs
in the bone marrow of secondary recipients. Statistical significance was calculated using a Student t test: *P , .05; **P , .01.
miR-29a/b-1 maintains HSC quiescence and promotes
cell survival
Because HSC quiescence is highly associated with self-renewal
capacity,29 we evaluated the cell cycle status of KO HSPCs. Although
KOLSK cells exhibited a significantly higher percentage of cells in the
S-G2-M phases of the cell cycle compared withWT littermate LSK cells
(Figure 4A; supplemental Figure 5), KO committed progenitors did not
exhibit alterations in cell cycle distribution (Figure 4B). To confirm that
these findings reflected differences in cell cycle progression, we as-
sessed cell cycle entry using BrdU incorporation assays and found that
LSK cells from KO mice cycled more rapidly than WT littermate
controls (41.63%vs 58.64% inG0, respectively;P, .05; supplemental
Figure 6). As decreased HSC number and reduced bone marrow cel-
lularity may be due to increased apoptosis, we performed annexin V
staining. KOmice exhibited a higher frequency of apoptotic LSK cells
(annexinV17-aminoactinomycinD (7-AAD)2) thanWT littermates. In
contrast, there was no difference in apoptosis observed in committed
progenitors (Figure 4C-D; supplemental Figure 7). Together, these
results demonstrate that miR-29a/b-1 loss impairs the maintenance of
quiescence and cell survival specifically in LSK cells, which are
composed of the most immature hematopoietic cells including HSCs
and MPPs.
miR-29a/b-1-null hematopoietic phenotype is due to
miR-29a loss
As themiR-29a/b-1KOmouseharbors a deletionof 2miRNAs, and the
miR-29 family is represented by 2 bicistrons including miR-29a/miR-
29b-1 on chromosome 7 and miR-29b-2/miR-29c on chromosome 1,
we sought to determine which miR-29 family member is responsible
for the miR-29a/b-1 KO HSPC phenotype. By quantitative real-time
polymerase chain reaction (qRT-PCR), we confirmed that miR-29a
expression was absent in c-Kit1 cells fromKOmice, whereasmiR-29b
and miR-29c expression were not significantly altered (Figure 5A).
Using retroviruses expressingmiR-29a ormiR-29b, only ectopic over-
expression of miR-29a in KO LSKs significantly increased colony
numbers (Figure 5B). Finally, the ability ofmiR-29a to reconstitute the
function of KO LSK cells was confirmed in transplantation assays in
which overexpression ofmiR-29a, but notmiR-29b, restoredKOdonor
cell chimerism in a multilineage fashion (Figure 5C; data not shown).
Together, these data indicate thatmiR-29a is responsible for the functional
defects observed in the KO mice, which we now refer to miR-29a-
deficient mice.
miR-29a promotes HSC differentiation by regulating multiple
target genes
In silico algorithms predict that miR-29a targets several hundred
mRNAs (eg, targetscan.org).7 However, the interactions between
miRNAs and their target genes depend on their relative expression
levels.30 To better understand the molecular pathways altered due to
loss of miR-29a in HSCs, we performed gene expression profiling of
FACS-purified HSCs (Lin2c-Kit1Sca-11CD342Slamf11) and com-
mitted progenitors (Lin2c-Kit1Sca-12) frommiR-29aKOmice.Using
a P value cutoff of ,.05, our analysis showed that miR-29a/b-1 ho-
mozygous deletion resulted in dysregulated expression of a larger
number of genes in HSCs (1238 genes) than in committed progenitor
cells (772 genes; Figure 6A). Unsupervised hierarchical clustering
analysis revealed that the KOHSCs exhibit an altered gene expression
profile compared with WT HSCs, and their expression patterns are
more closely related to WT committed progenitors than WT HSCs
(Figure 6B). Gene set enrichment analysis31 demonstrated a significant
enrichment of cell cycle regulators in KO HSCs, consistent with their
Figure 4. Deletion of miR-29a/b-1 is associated with
increased HSPC cell cycling and apoptosis. (A-B) Cell
cycle analysis by staining DNA content of fixed cells
with DAPI. Fewer LSK cells, but not committed pro-
genitor cells, accumulated in the G1/G0 stages of the
cell cycle in miR-29a KO mice. (C-D) Increased num-
bers of annexin V1 LSK cells, but not myeloid pro-
genitor cells, were present in bothmiR-29a KO and Het
mice compared with WT. Details of annexin V staining
and cell cycle staining for specific HSPC populations
are summarized in supplemental Figures 5 and 7. Error
bars indicate SEM. Each group has 7 to 10 mice from
different experiments. Statistical significance was cal-
culated using a Student t test: *P , .05; **P , 0.01.
altered cell cycle status (supplemental Figure 8). In an unsupervised
hierarchical clustering analysis considering predicted miR-29a target
genes,7,23 we identified a group of these genes similarly expressed in
WT andmiR-29a-null committed progenitors, but significantly upreg-
ulated in miR-29a-null HSCs compared with WT HSCs. These genes
included Dnmt3a, Diablo, Spast, Cdc7, Clk2, Kdelc1, Nasp, Ywhae,
Calm3, Larp4, and Chmp6 (Figure 6C). To validate our microarray
results, we performed qRT-PCR to measure the expression of dys-
regulatedmiR-29a target genes and additional genes that regulate HSC
function using c-Kit1 bone marrow cells from the KO and WT litter-
mates. We confirmed the increased expression of predicted miR-29a
targets in KO cells, as well as additional genes that regulate HSC
function such as p21, p27, Bmi1, Gata2, and TP53 (Figure 6D-E).
miR-29a regulates HSC function in part through inhibition
of Dnmt3a
Transcriptional profiling revealed that Dnmt3a transcript levels were
increased 1.55-fold in miR-29a-null HSCs compared with WT HSCs
(P5 .03), and this result was confirmed by qRT-PCR (Figure 6D). As
miR-29 has been shown to target DNAmethyltransferase 3a (Dnmt3a)
in the context of cancer,32,33 and Dnmt3a plays a prominent role in
maintainingHSC function and lineage commitment34 and is frequently
mutated in acute myeloid leukemia,35-37 we investigated whether
Dnmt3a is required for themiR-29a-deficient HSPCphenotype. To test
whether Dnmt3a deficiency can restore normal function in miR-29a-
null HSCs, we knocked down Dnmt3a in LSK cells using 2 retroviral
shRNAs (196 and 6567) that had been previously validated in NIH/3T3
cells (Figure 7A; supplemental Figure 9). After Dnmt3a shRNA-
transduced LSK cells (GFP1) were double FACS-sorted and plated
into methylcellulose media, KO LSK cells demonstrated a significant
increase in colony formation capacity compared with vector controls
(Figure 7B).
To confirm thatmiR-29a andDnmt3a functionally interact in vivo,
we crossedmice deficient inmiR-29a andDnmt3a and found that LSK
cell frequencies were similar in WT and Het Dnmt3a mice, and
miR-29a Het LSKs were significantly decreased compared with both
WT and Het Dnmt3a mice. Mice heterozygous for both Dnmt3a and
miR-29a exhibited significantly higher frequencies of LSK cells than
miR-29a Het mice, but committed progenitor cell frequencies were
unaltered (Figure 7C). This restoration of miR-29a Het LSK cell
number on Dnmt3a loss was associated with increased quiescence,
supporting a central role of Dnmt3a in the cell cycle alterations ob-
served inmiR-29aKOHSCs (Figure 7D).Dnmt3amRNA expression
was upregulated in miR-29a heterozygous LSK cells, and Dnmt3a
mRNA levels were restored to WT levels in mice compound hetero-
zygous for Dnmt3a and miR-29a (supplemental Figure 10A). In con-
trast, miR-29a expression levels were unaltered in Dnmt3a-deficient
LSKcells (supplemental Figure 10B). Together, these data indicate that
Dnmt3a expression is regulated by miR-29a, and that de-repression of
Dnmt3a expression in the context ofmiR-29a contributes to the defects
observed in miR-29a Het and KO HSCs.
To determine whether Dnmt3a reduction can restore miR-29a-
deficient HSC function in vivo, we competitively transplanted 5 million
total bone marrow cells fromWT littermates,miR-29a1/2,Dnmt3a1/2,
and miR-29a1/2;Dnmt3a1/2 mice into lethally irradiated congenic re-
cipients each along with 5 million competitors. Peripheral blood donor
cell chimerism was significantly higher in mice transplanted with
compound miR-29a1/2;Dnmt3a1/2 cells compared with those trans-
planted with miR-29a1/2 cells 6 months following transplant
(Figure 7E). Mice transplanted with miR-29a Het cells exhibited
significantly lower donor chimerism among immature hematopoietic
cells, but miR-29a1/2;Dnmt3a1/2 HSCs demonstrated competitive
long-term reconstitution capacity similar to that observed with WT
donors when the recipient’s BM and spleenwere evaluated (Figure 7F;
supplemental Figure 10C-D). We also evaluated HSC function from
Figure 5. Overexpression of miR-29a, but not miR-
29b, rescues the self-renewal defect in miR-29a/
b-1-null HSCs. Transcript levels of miR-29 members
were measured in (A) c-Kit-enriched cells. (B) Methyl-
cellulose colony forming capability of LSK cells after
retroviral overexpression of miR-29a or miR-29b in
miR-29a/b-1-null HSPCs. Twenty-four hours following
transduction, GFP1 cells were sorted, and 300 were
plated per well. Each group represents experiments
using 2 mice, with wells plated in triplicate. (C) Trans-
plantation of 300 000 LSK cells from WT or miR-29a/b-1-
null HSPCs retrovirally transduced with miR-29a, -29b,
or GFP control (n 5 6-10 mice per group). Peripheral
blood analysis was performed 16 weeks after trans-
plantation. Data represent the aggregate of 2 indepen-
dent experiments. Error bars indicate SEM. Statistical
significance was calculated using a Student t test:
*P , .05.
mice expressing reduced levels of miR-29a, Dnmt3a, or both by com-
petitive transplantation. Evaluation of the peripheral blood 16 weeks
following transplant revealed that deletion of Dnmt3a increased the
reconstitution capacity of miR-29a-null HSCs compared with WT
HSCs, consistent with findings previously observed,34 and this effect
was slightly reduced in the setting ofmiR-29a heterozygosity.Dnmt3a
heterozygosity resulted in a small, but statistically significant, increase
in donor cell chimerism in the miR-29a-null background (supplemen-
tal Figure 11). Together, these data confirm that Dnmt3a is a critical
downstream mediator of miR-29a function in HSCs.
Discussion
In this study, we assessed the role of miR-29a in hematopoiesis by
evaluating mice lacking the miR-29a/b-1 bicistron. Our studies reveal
that miR-29a maintains HSC self-renewal and that Dnmt3a is a direct
target of miR-29a that mediates the miR-29a-deficient hematopoietic
phenotype. Thus, miR-29a is among a small but growing group of
miRNAs shown to regulate HSC function. However, unlike other
miRNA regulators of HSC function, which have been shown
to regulate apoptosis or transforming growth factor-b signaling
(miR-125),12,14 PI3K/AKT/GSK3b signaling (miR-126),15 or nuclear
factor-kBsignaling16 (miR-146),miR-29a appears to largelymediate
its effects on HSC function by regulating the epigenetic state of
HSCs by directly inhibiting expression of the DNA methyltransfer-
ase enzyme, DNMT3a.
ThemiR-29a/b-1-null phenotype is specifically due to loss ofmiR-
29a because only ectopic expression of miR-29a, but not miR-29b,
restored both the in vitro colony forming and long-term reconstitution
ability of miR-29a/b-1-deficient HSPCs. These findings are consistent
with our previous studies in which we demonstrated that overex-
pression of miR-29a, but not miR-29b, is sufficient to induce myeloid
leukemia by conferring self-renewal to committed myeloid progeni-
tors.9 Collectively, these findings provide further evidence that mem-
bers of the samemiRNA familymay exert distinct biological functions.
The biological basis of the unique effects of miR-29a and miR-29b in
Figure 6. Gene expression profiling analysis re-
veals dysregulation ofmiR-29a targets in HSCs. (A)
Numbers of differentially expressed genes in miR-
29a/b-1 KO or WT HSCs (Lin2c-Kit1Sca-11CD342
Slam1) or committed progenitor (Lin2c-Kit1Sca-12;
Prog) cells. Genes were selected using a P value
threshold of ,.05 and a fold change .1.5. (B) Un-
supervised clustering analysis of dysregulated genes
identified in A. (C) Unsupervised clustering analysis
of genes predicted to be targets of miR-29a. Pre-
dicted targets were identified using targetscan.
org (Release 6.1). (D) Validation of changes in the
expression levels of reported regulators of bone
marrow HSPCs using c-Kit-enriched bone marrow
cells from miR-29a/b-1 WT or KO mice by qRT-PCR.
Fold change was calculated by comparing KO with
WT cells. The genes shown represent predicted miR-
29a target genes with fold change .1 in miR-29a/b-1
KOs compared with WT littermates. (E) Selected reg-
ulators of HSC function were chosen based on pub-
lished genetic evidence. Fold change was relative to
WT type. Error bars represent SEM from triplicate
experiments.
Figure 7. Dnmt3a dysregulation mediates miR-29a/b-1-deficient HSC defects. (A) shRNAs (197 and 6567) efficiently knock down Dnmt3a mRNA levels by qRT-PCR
in NIH 3T3 cells. (B) Knock down of Dnmt3a partially restores miR-29a/b-1-null HSPC function as assessed by methylcellulose colony formation assay. Bone marrow
cells were harvested from fluorouracil (5-FU) treated mice and infected with either empty GFP1 retrovirus or shRNAs against Dnmt3a. GFP1 cells were double-sorted after
2 rounds of infection and plated in 6-well plates with 200 cells per well, and colony numbers were counted at day 12. (C) The 3- to 4-week-old progeny from miR-29a1/2
Dnmt3awt/fl[Mx1-Cre] mice were treated with poly I:C 3 times every other day and were analyzed 1 month following the last injection. LSK (left) cells were significantly
increased in miR-29a1/2;Dnmt31/2 mice, but committed progenitors were not affected (right). (D) Evaluation of cell cycle status of LSK cells in miR-29a1/2, Dnmt3a1/2, and
miR-29a1/2;Dnmt3a1/2 mice using a DAPI DNA stain. Shown with representative flow cytometry analysis (left) and summarized results (right). (E) Five million total bone
marrow cells from miR-29a1/1;Dnmt3a1/1, miR-29a1/2;Dnmt3a1/1, miR-29a1/1;Dnmt3a1/2, and miR-29a1/2;Dnmt3a1/2 mice were transplanted into lethally irradiated
congenic recipients with 5 million competitor bone marrow cells. Peripheral blood donor chimerism was determined 4 months after transplant. (F) Bone marrow HSPCs were
analyzed for donor cell chimerism. Error bars represent SEM from 5 to 12 mice for all experiments shown. Statistical significance was calculated using a Student t test:
*P , .05; **P , .01.
HSCs is not due to their tissue-specific expression, which has been
shown for the thymus,19 but likely due to a unique 39 hexanucleotide
nuclear localization sequence in miR-29b, which has been shown to
enhance its turnover during nonmitotic portions of the cell cycle.38
Dnmt3a is a primary mediator of the miR-29a-deficient hemato-
poietic phenotype, as shRNA-mediated reduction ofDnmt3a activity in
miR-29a2/2 HSPCs partially restored their in vitro colony formation
capacity. In addition, deleting one allele ofDnmt3a inmiR-29a/b-11/2
mice restored HSC function, demonstrated by recovery of HSC fre-
quencies and their long-term reconstitution capacity. These studies
are consistent with prior studies demonstrating the essential role of
DNAmethyltransferases inmaintainingHSC function; loss ofDnmt3a
resulted in expanded HSC numbers, impaired HSC reconstitution
activity, and defects in differentiation,34,39 whereas ectopic Dnmt3a
expression inhibited cell proliferation and survival.34 Additional data
supporting the physiologic relevance ofmiR-29a regulation ofDnmt3a
come from gene expression studies, which show that both miR-29a
and Dnmt3a are highly enriched in HSCs.9,34 Thus, Dnmt3a is
a physiologically relevant target of miR-29a, indicating that miR-29a
regulates the balance between HSC self-renewal and differentiation/
proliferation through a novel epigenetic mechanism. Nevertheless, the
difference in HSC function between WT mice and miR-29a1/2;
Dnmt3a1/2mice suggests that other miR-29a targets likely contribute
to themiR-29a-null phenotype. Possible candidates contributing to this
phenotype include predicted direct miR-29a target genes revealed by
themiR-29a/b-12/2HSC transcriptome including Cdk6,40 Tcl1,41 and
Hbp1.9 Notably,miR-29a2/2HSCs exhibited dysregulated expression
of numerous cell cycle regulators, reflecting their impaired ability to
maintain quiescence, and it is likely that the observed increased cell
cycling underlies, or at least reflects, the alteration inmiR-29a2/2HSC
function, as has been shown for other mouse mutants exhibiting
increased HSC cycling and reduced function.42
We previously reported that miR-29a is expressed at high levels in
human AML compared with purified HSPCs and that enforced ex-
pressionofmiR-29a inHSPCs is sufficient to drive amyeloproliferative
phenotype and confer aberrant self-renewal to committed myeloid
progenitors, supporting miR-29a as an important regulator of self-
renewal.9 However, it appears that miR-29a’s function is cell context
specific, as enforced expression of miR-29a or miR-29b suppresses
AMLcell proliferation and survival, providing a rationale formiR-29b-
based therapies to treat AML patients.32,43 Thus, because miR-29a
is critical for maintaining HSC self-renewal and miR-29 negatively
influences AML cell growth, miR-29 agonist therapies would be ex-
pected to provide simultaneous negative growth effects on AML cells
while promoting HSC self-renewal. However, given the presence of
preleukemicHSCs in AMLpatients,44-46 whether or not such therapies
may promote the growth or transformation of such preleukemic HSCs
is of potential concern. Thus, examining the effect of miR-29-based
therapies on preleukemic HSCs will be an important area of investi-
gation in the future.
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